Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.
Results of recent animal studies have lent support to the hypothesis that hyperlipidaemia may contribute to renal injury. This report documents the case of a 15-year-old boy with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis (FGS) who showed an improvement in renal function and proteinuria as a result of treatment with low-density lipoprotein aphaeresis (LDL-A) combined with pravastatin. Although further work is required to determine the efficacy of lipid-lowering therapy in progressive glomerular disease in humans, the combination of LDL-A and pravastatin is likely be included in the choice of treatment modalities available for patients with drug-resistant nephrotic syndrome due to FGS.
Hattori
M
M
Department of Paediatric Nephrology, Tokyo Women's Medical College, Japan.
Ito
K
K
Kawaguchi
H
H
Tanaka
T
T
Kubota
R
R
Khono
M
M
D000293:Adolescent; D001781:Blood Component Removal; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications*; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007677:Kidney Function Tests; D008077:Lipoproteins, LDL / Q000627:therapeutic use*; D008297:Male; D009404:Nephrotic Syndrome / Q000209:etiology / Q000628:therapy*; D017035:Pravastatin / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D008077:Lipoproteins, LDL; D017035:Pravastatin